FDA Briefing Document May 4,2004 Oncologic Drugs Advisory Committee Safety Concerns Associated with Aranesp
نویسندگان
چکیده
منابع مشابه
Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key in sepsis modulation?
38. Canaud B, Mingardi G, Braun J et al. STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23: 3654–3661 39. Levin NW, Fishbane S, Cañedo FV et al. MAXIMA Study Investigators. Intravenous methoxy polyethylene glyc...
متن کاملMembers / Guests FROM : Maraviroc Review Team THROUGH : Edward Cox
The purpose of this document is to provide the Antiviral Products’ Advisory Committee with a summary of FDA analyses of data submitted in support of a request for accelerated approval of maraviroc, the first in a new class of antiretroviral drugs called CCR5 receptor antagonists. During the Advisory Committee meeting to be held on April 24, 2007, the Committee will be asked to consider the safe...
متن کاملFDA fails to reduce accessibility of paracetamol despite 450 deaths a year.
BMJ VOLUME 325 28 SEPTEMBER 2002 bmj.com Staff at the Food and Drug Administration’s Office of Drug Safety wanted the United States to consider following the United Kingdom’s policy of reducing the public’s ease of access to paracetamol to try to reduce the number of deaths from overdose, a concern in both these countries. But the office’s views never reached the FDA’s nonprescription drugs adv...
متن کاملThe FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
T he Trial to Reduce Cardiovascular Endpoints with Aranesp Therapy (TREAT) (1) has prompted the Food and Drug Administration (FDA) to reevaluate the use of erythropoiesis-stimulating agents (ESAs) in the treatment of chronic kidney disease (CKD) anemia (2). An FDA public advisory committee meeting in 2010 is anticipated. The TREAT study reported, against placebo, minimal benefit and increased r...
متن کاملThe cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
n engl j med nejm.org 1 Administration (FDA) considers a decrease in glycated hemoglobin an approvable end point, very intensive glycemic control is associated with increased cardiovascular and all-cause mortality.1 The safety of specific drugs for type 2 diabetes — particularly the thiazolidinediones — has also been questioned. After rosiglitazone had been approved in the United States in 1999...
متن کامل